Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors

Journal of Leukocyte Biology

Volumn 90, Issue 5, 2011, Pages 875-882

  Airoldi, Irma ^a   Ribatti, Domenico ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Angiogenesis; Antiangiogenesis; Multiple myeloma; Non small cell lung carcinoma

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 12; INTERLEUKIN 27; INTERLEUKIN 8; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CELL FUNCTION; CELL INFILTRATION; ENDOTHELIUM CELL; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPETENT CELL; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; TUMOR; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR MODEL;

ANGIOGENESIS INHIBITORS; ANIMALS; CHEMOKINES, CXC; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-12; INTERLEUKINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 80055087804     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0511237     Document Type: Review

References (59)

1. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F., Sharpe, R. J. (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247, 77-79.
2. Gupta, S. K., Singh, J. P. (1994) Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J. Cell Biol. 127, 1121-1127.
3. Gengrinovitch, S., Greenberg, S. M., Cohen, T., Gitay-Goren, H., Rockwell, P., Maione, T. E., Levi, B. Z., Neufeld, G. (1995) Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms. J. Biol. Chem. 270, 15059-15065.
4. Perollet, C., Han, Z. C., Savona, C., Caen, J. P., Bikfalvi, A. (1998) Platelet factor 4 modulates fibroblast growth factor-2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 91, 3289-3299.
5. Struyf, S., Burdick, M. D., Proost, P., Van Damme, J., Strieter, R. M. (2004) Platelets release CXCL4L1, a non allelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ. Res. 95, 855-857.
6. Strieter, R. M., Belperio, J. A., Phillips, R. J., Keane, M. P. (2004) CXC chemokine in angiogenesis of cancer. Semin. Cancer Biol. 14, 195-200.
7. Romagnani, P., Lasagni, L., Annunziato, F., Serio, M., Romagnani, S. (2004) CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 25, 201-209.
8. Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., Chan, S. Y., Roczniak, S., Shanafelt, A. B. (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348-27357.
9. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Morris, S. B., Burdick, M. D., Glass, M. C., Taub, D. T., Iannettoni, M. D., Whyte, R. I., Strieter, R. M. (1996) Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184, 981-992.
10. Weng, Y., Siciliano, S. J., Waldburger, K. E., Sirotina-Meisher, A., Staruch, M. J., Daugherty, B. L., Gould, S. L., Springer, M. S., DeMartino, J. A. (1998) Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J. Biol. Chem. 273, 18288-18291.
11. Romagnani, P., Annunziato, F., Lasagni, L., Lazzeri, E., Beltrame, C., Francalanci, M., Uguccioni, M., Galli, G., Cosmi, L., Maurenzig, L., Baggiolini, M., Maggi, E., Romagnani, S., Serio, M. (2001) Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J. Clin. Invest. 107, 53-63.
12. Lasagni, L., Francalanci, M., Annunziato, F., Lazzeri, E., Giannini, S., Cosmi, L., Sagrinati, C., Mazzinghi, B., Orlando, C., Maggi, E., Marra, F., Romagnani, S., Serio, M., Romagnani, P. (2003) An alternatively spliced variant of CXCR3 mediated the inhibition of endothelial cell growth induced by IP-10, Mig, I-TAC, and acts as a functional receptor for platelet factor 4. J. Exp. Med. 197, 1537-1549.
13. Sulpice, E., Bryckaert, M., Lacour, J., Contreres, J. O., Tobelem, G. (2002) Platelet factor 4 inhibits FGF-2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not the phosphatidylinositol 3-kinase pathway. Blood 100, 3087-3094.
14. Gentilini, G., Kirschbaum, N. E., Augustine, J. A., Aster, R. H., Visentin, G. P. (1999) Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, plaletel factor-4 (PF-4), is associated with impaired downregulation of p21 Cip1/Waf1. Blood 93, 25-33.
15. Jouan, V., Canron, X., Alemany, M., Caen, J. P., Quentin, G., Plouet, J., Bikfalvi, A. (1999) Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 94, 984-993.
16. Legler, D. F., Loetscher, M., Roos, R. S., Clark-Lewis, I., Baggiolini, M., Moser, B. (1998) B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J. Exp. Med. 187, 655-660.
17. Jenh, C. H., Cox, M. A., Hipkin, W., Lu, T., Pugliese-Sivo, C., Gonsiorek, W., Chou, C. C., Narula, S. K., Zavodny, P. J. (2001) Human B cell-attracting chemokine 1 (bca-1; cxcl13) is an agonist for the human CXCR3 receptor. Cytokine 15, 113-121.
18. Teicher, B. A., Fricker, S. P. (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res. 16, 2927-2931.
19. Belperio, J. A., Keane, M. P., Arenberg, D. A., Addison, C. L., Ehlert, J. E., Burdick, M. D., Strieter, R. M. (2000) CXC chemokines in angiogenesis. J. Leukoc. Biol. 68, 1-8.
20. Kijowski, J., Baj-Krzyworzeka, M., Majka, M., Reca, R., Marquez, L. A., Christofidou-Solomidou, M., Janowska-Wieczorek, A., Ratajczak, M. Z. (2001) The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic stem cells. Stem Cells 19, 453-466.
21. Heidemann, J., Ogawa, H., Rafiee, P., Lugering, N., Maaser, C., Domschke, W., Binion, D. G., Dwinell, M. B. (2004) Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 286, G1059-G1068.
22. Struyf, S., Burdick, M. D., Peeters, E., Van den Broekck, K., Dillen, C., Proott, P., Van Damme, J., Strieter, R. M. (2007) Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 67, 5940-5948.
23. Sgadari, C., Angiolillo, A. L., Cherney, B. W., Pike, S. E., Farber, J. M., Koniaris, L. G., Vanguri, P., Burd, P. R., Sheikh, N., Gupta, G., et al. (1996) Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93, 13791-13796.
24. Sgadari, C., Angiolillo, A. L., Tosato, G. (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87, 3877-3882.
25. Tanaka, T., Manome, Y., Wen, P., Kufe, D. W., Fine, H. A. (1997) Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat. Med. 3, 437-442.
26. Homey, B., Muller, A., Zlotnik, A. (2002) Chemokines: agents for the immunotherapy of cancer? Nat. Rev. Immunol. 2, 175-184.
27. Yang, J., Richmond, A. (2004) The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. 9, 846-855.
28. Frederick, M. J., Henderson, Y., Xu, X., Deavers, M. T., Sahin, A. A., Wu, H., Lewis, D. E., El-Naggar, A. K., Clayman, G. L. (2000) In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am. J. Pathol. 156, 1937-1950.
29. Schwarze, S. R., Luo, J., Isaacs, W. B., Jarrard, D. F. (2005) Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64, 67-74.
30. Salcedo, R., Ponce, M. L., Young, M. A., Wasserman, K., Ward, J. M., Kleinman, H. K., Oppenheimer, J. J., Murphy, W. J. (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96, 34-40.
31. Hong, K. H., Ryu, J., Han, K. H. (2005) Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105, 1405-1407.
32. Goede, V., Brogelli, L., Ziche, M., Augustin, H. G. (1999) Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int. J. Cancer 82, 765-770.
33. Salcedo, R., Young, H. A., Ponce, M. L., Ward, J. M., Kleinman, H. K., Murphy, W. J., Oppenheimer, J. J. (2001) Eotaxin (CCL11) induces in vivo angiogenic response by human CCR3+ endothelial cells. J. Immunol. 166, 7571-7578.
34. Strasly, M., Doronzo, G., Cappello, P., Valdembri, D., Arese, M., Mitola, S., Moore, P., Alessandri, G., Giovarelli, M., Bussolino, F. (2004) CCL16 activates an angiogenic program in vascular endothelial cells. Blood 103, 40-49.
35. Sharma, S., Yang, S. C., Hillinger, S., Zhu, L. X., Huang, M., Batra, R. K., Lin, J. F., Burdick, M. D., Strieter, R. M., Dubinett, S. M. (2003) SLC/ CCL21-mediated anti-tumor responses require IFN γ, MIG/CXCL9 and IP10(CXCL10). Mol. Cancer 2, 22.
36. Sharma, S., Stolina, M., Luo, J., Strieter, R. M., Burdick, M., Zhu, L. X., Batra, R. K., Dubinett, S. M. (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. 164, 4558-4563.
37. Hillinger, S., Yang, S. C., Zhu, L., Huang, M., Duckett, R., Atianzar, K., Batra, R. K., Strieter, R. M., Dubinett, S. M., Sharma, S. (2003) EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-γ-dependent antitumor responses in a lung cancer model. J. Immunol. 171, 6457-6465.
38. Strieter, R. M., Burdick, M. D., Mestas, J., Gomperts, B., Keane, M. P., Belpiero, J. A. (2006) Cancer CXC chemokine networks and tumor angiogenesis. Eur. J. Cancer 42, 768-778.
39. Yoshimoto, T., Morishima, N., Mizoguchi, I., Shimizu, M., Nagai, H., Oniki, S., Oka, M., Nishigori, C., Mizuguchi, J. (2008) Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180, 6527-6535.
40. Cocco, C., Giuliani, N., Di Carlo, E., Ognio, E., Storti, P., Albetino, M., Sorrentino, C., Ponzoni, M., Ribatti, D., Airoldi, I. (2010) Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 16, 4188-4197.
41. Cocco, C., Canale, S., Frasson, C., Di Carlo, E., Ogni, E., Ribatti, D., Prigione, I., Basso, G., Airoldi, I. (2010) Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood 116, 3887-3898.
42. Airoldi, I., Di Carlo, E., Cocco, C., Taverniti, G., D'Antuono, T., Ognio, E., Watanabe, M., Ribatti, D., Pistoia, V. (2007) Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc. Natl. Acad. Sci. USA 104, 3996-4001.
43. Airoldi, I., Cocco, C., Giuliani, N., Ferrarini, M., Colla, S., Ognio, E., Taverniti, G., Di Carlo, E., Cutrona, G., Perfetti, V., Rizzoli, V., Ribatti, D., Pistoia V. (2008) Constitutive expression of IL-12R β 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 112, 750-759.
44. Airoldi, I., Di Carlo, E., Cocco, C., Caci, E., Cilli, M., Sorrentino, C., Sozzi, G., Ferrini, S., Rosini, S., Bertolini, G., Truini, M., Grossi, F., Galietta, L. J., Ribatti, D., Pistoia, V. (2009) IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS ONE 4, e6119.
45. Airoldi, I., Di Carlo, E., Banelli, B., Moserle, L., Cocco, C., Pezzolo, A., Sorrentino, C., Rossi, E., Romani, M., Amadori, A., Pistoia, V. (2004) The IL-12Rβ2 gene functions as a tumor suppressor in human B cell malignancies. J. Clin. Invest. 113, 1651-1659.
46. Ferretti, E., Di Carlo, E., Cocco, C., Ribatti, D., Sorrentino, C., Ognio, D., Montagna, D., Pistoia, V., Airoldi, I. (2010) Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol. Lett. 133, 99-105.
47. Sica, A., Schioppa, T., Mantovani, A., Allavena, P. (2006) Tumor-associated macrophages are a distinct M2 polarized population promoting tumou progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727.
48. Trinchieri, G., Pflanz, S., Kastelein, R. A. (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19, 641-644.
49. Airoldi, I., Cocco, C., Di Carlo, E., Disarò, S., Ognio, E., Basso, G., Pistoia, V. (2006) Methylation of the IL-12Rβ2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res. 66, 3978-3980.
50. Cocco, C., Morandi, F., Airoldi, I. (2011) IL-27 and IL-23 modulate human plasma cell functions. J. Leukoc. Biol. 89, 729-734.
51. Gollob, J. A., Mier, J. W., Veenstra, K., McDermott, D. F., Clancy, D., Clancy, M., Atkins, M. B. (2000) Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. 6, 1678-1692.
52. Lacy, M. Q., Jacobus, S., Blood, E. A., Kay, N. E., Rajkumar, S. V., Griepp, P. R. (2009) Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk. Res. 33, 1485-1489.
53. Anwer, K., Barnes, M. N., Fewell, J., Lewis, D. H., Alvarez, R. D. (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther. 17, 360-369.
54. Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., Neri, D. (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264-269.
55. Robertson, M. J., Cameron, C., Atkins, M. B., Gordon, M. S., Lotze, M. T., Sherman, M. L., Ritz, J. (1999) Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 5, 9-16.
56. Colombo, M. P., Trinchieri, G. (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168.
57. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., De Coste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., Sherman, M. L. (1997) Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3, 409-417.
58. Portielje, J. E., Kruit, W. H., Schler, M., Beck, J., Lamers, C. H., Stoter, G., Huber, C., de Boer-Dennert, M., Rakhit, A., Bolhuis, R. L., Aulitzky, W.E. (1999) Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. 5, 3983-3989.
59. Zhu, S., Lee, D. A., Li, S. (2010) IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J. Immunol. 184, 2348-2354.